Phosphodiesterase Type 5 (PDE-5) Inhibitor Utilization Among Women

Basic Details
Date Posted
Thursday, October 11, 2018
Status
Complete
Medical Product
phosphodiesterase type 5 (PDE5) inhibitor
Description

The goal of this query was to estimate phosphodiesterase type 5 (PDE5) inhibitor utilization among women in the Sentinel Distributed Database (SDD). Report 1 contains estimates of phosphodiesterase type 5 (PDE5) inhibitor use among reproductive-aged women. Report 2 contains estimates of PDE5 inhibitor use that occurred during a pregnancy ending in a live-born delivery or within 90 days prior to pregnancy start, among women. Data from January 1, 2001 to March 31, 2018 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on August 27, 2018. 

Deliverables (2)
Sentinel Modular Program Report: Phosphodiesterase Type 5 (PDE5) Inhibitor Utilization Among Reproductive-Aged Women, Report 1 Sentinel Modular Program Report: Phosphodiesterase Type 5 (PDE5) Inhibitor Utilization Among Pregnant Women, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2001 - March 31, 2018
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Females 15 to 50 years of age
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Phosphodiesterase Type 5 (PDE5) Inhibitors & Exposure in Pregnancy
2019 ICPE Poster: Phosphodiesterase Type 5 (PDE-5) Inhibitor Use Among Pregnant Women and Women of Reproductive Age in the United States
Phosphodiesterase Type 5 Inhibitor Use Among Pregnant and Reproductive‐Age Women in the United States